Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
信迪利单抗联合贝伐珠单抗、奥沙利铂和卡培他滨作为RAS突变、微卫星稳定、不可切除的转移性结直肠癌一线治疗方案：一项开放标签、单臂II期试验
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.102123
Fang, Xuefeng; Zhu, Ning; Zhong, Chenhan; Wang, Liuhong; Li, Jun; Weng, Shanshan; Hu, Hanguang; Dong, Caixia; Li, Dan; Song, Yongmao; Xu, Dong; Wang, Jianwei; Sun, Lifeng; Wang, Jian; Wang, Zhanhuai; Cao, Hongfeng; Liao, Xiujun; Yu, Ningjuan; Xiao, Qian; Mi, Mi; Zhang, Suzhan; Ding, Kefeng; Yuan, Ying
